Avellino, a leader in precision medicine, is making a global impact in genetics and bringing innovative
diagnostics, therapies, and AI-driven data processing to patient care.
AvaGen is the first genetic test for determining risk of keratoconus and the presence
corneal dystrophies. Returning to the United States in 2021.
The Avellino SARS-CoV-2/COVID-19 Test (AvellinoCoV2) is a non-invasive, swab based
test used to detect the SARS-CoV-2 virus.
Our mission is to bring personalized medicine to eyecare professionals by delivering actionable
information derived from the unique genes of individual patients.
Avellino collaborates with best-in-class partners to create first-in-class genetic tests and
gene-editing therapies. These collaborations provide the chance to integrate precision medicine into
existing healthcare practices and ultimately improve them.
Data must be straightforward for precision medicine to be properly integrated into clinical care.
Avellino provides multiple layers of support in the patient treatment process to assist the clinician
with interpreting results, explaining results to patients, delivering personalized treatment, and
improving patient outcomes.
At its very core, precision medicine begins with genetics. Tailoring treatment relies on recognizing
individual characteristics and a patient’s unique susceptibility to certain diseases. For Avellino, providing
real genetic data that correlate with those susceptibilities is the key.
Avellino is building upon the success of its own proprietary Universal test, the world's first DNA test
confirming the presence of genetic indicators positively associated with corneal dystrophies. Our latest
preemptive diagnostic tool, AvaGen, addresses keratoconus in addition to corneal dystrophies, and is set to
expand to address Fuchs’ dystrophy, glaucoma, and a wide range of other eye diseases in the near future.